| Hazard Information | Back Directory | [Description]
SRTCX1003 is a SIRT1 activator which suppresses inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. | [Uses]
SRTCX1003 is an orally active SIRT1 activator. SRTCX1003 suppresses inflammatory responses[1]. | [in vivo]
SRTCX1003 (3-100 mg/kg; oral; once) decreases LPS (HY-D1056)-stimulated TNFα and IL-12p40 production in mice inflammation model[1]. | Animal Model: | Male BALB/c mice, LPS-induced inflammation mouse model[1] | | Dosage: | 3, 10, 30 and 100 mg/kg | | Administration: | Oral, 60 minutes prior to LPS administration | | Result: | Dose-dependently reduced LPS-stimulated TNFα and IL-12p40 production. |
| [References]
[1] Yang H, et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. DOI:10.1371/journal.pone.0046364 |
|
|